Pfizer's Aromasin prevents breast cancer in high risk subjects
This article was originally published in Scrip
Executive Summary
Pfizer's aromatase inhibitor Aromasin (exemestane) reduces the risk of breast cancer by 65% compared with placebo in women who are at increased risk of developing the disease, according to an international trial conducted by the NCIC Clinical Trials Group.